Rapt Therapeutics Acquired by GSK — Healthcare M&A

GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics in a strategic healthcare deal valued at $2.2 billion. The transaction is designed to expand GSK’s pharmaceutical pipeline with Rapt’s lead program, ozureprubart (RPT904), a mid-stage anti-immunoglobulin E (IgE) monoclonal antibody being developed for food allergy. The candidate is intended to offer every-12-week dosing, aiming to differentiate from current standard-of-care regimens that typically require more frequent administration.

Rapt’s focus on immunology and food allergy aligns with GSK’s broader strategy of adding assets targeting validated mechanisms where there is unmet medical need. Food allergy remains a significant clinical and economic burden, with millions of patients affected in the U.S. and substantial reliance on healthcare services for reactions. By bringing ozureprubart into its portfolio, GSK is positioning to address limitations of existing therapies, including patient eligibility constraints and treatment burden for predominantly pediatric populations.

While the announcement confirms the headline valuation and the pipeline rationale, specific closing timing and detailed deal mechanics were not provided in the available information. The acquisition is expected to progress through customary regulatory and shareholder approvals before completion.